Oxford Nanopore Technologies is for Research Use Only (RUO) and is not intended for use in diagnostic procedures
Public source
Publisher name
Public post
“For decades…you'd have to take a sample and order a multitude of tests for things like viruses and bacteria. That delay costs time, money, medicine, and sometimes lives…
Company
Oxford Nanopore Technologies
Our goal is to enable the analysis of anything, by anyone, anywhere.
- Industry
- Biotechnology Research
- Location
- Oxford, GB
- Company size
- 1,001–5,000 employees
About Oxford Nanopore Technologies
Oxford Nanopore Technologies plc was founded in 2005 as a spin-out from the University of Oxford. The company now employs more than 1000 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Francis Van Parys, has a track record of delivering disruptive technologies to the market.
See moreLatest activity
Latest activity from Oxford Nanopore Technologies
15 signals
Products & Services
Oxford Nanopore Technologies introduced the Direct RNA Barcoding Kit, allowing multiple samples to be analysed together in practice.
Research & Knowledge
Oxford Nanopore Technologies sequenced sludge from 83 plants around the world using sequencing to assemble 53,501 genomes spanning over 12,000 microbial species, most never described before.
Presence & Recognition
Oxford Nanopore Technologies attended the Genomics India Conference 2026, featuring speakers including Pritam Sarkhel, Shivang Agarwal, Harpreet Kukreja, Jawahar Swaminathan, and Oxford Nanopore Technologies.
Discover more
Similar signals
Similar public activity from other companies.
Legal & Regulatory
Cepheid
Cepheid has received Emergency Use Listing (EUL) from the World Health Organization for its Xpert Hemorrhagic Fever Panel to support efforts during the Ebola outbreak in the Democratic Republic of the Congo.
Legal & Regulatory
OGT
OGT is committed to transitioning the full CytoCell IVDD portfolio to IVDR by the 31 December 2028 deadline alongside a broad range of non-IVDD probes such as existing custom myProbes.
Legal & Regulatory
Simsen Diagnostics
Simsen Diagnostics has an ISO 15189 application in progress for its ctDNA analysis in the EU under GDPR.
Legal & Regulatory
ANCHOR Diagnostics
ANCHOR Diagnostics has successfully completed its recent re-audit and been awarded its new ISO 13485 Quality Management System certificate by mdc GmbH.
Legal & Regulatory
Touchlight